Inzaule S. C., Jordan M. R., Cournil Amandine, Vitoria M., Ravasi G., Cham F., Le L. V., Dzangare J., Hamunime N., Mutenda N., Aghokeng Fobang Avelin, Bissek A., Billong S., Kaleebu P., Doherty M., Bertagnolio S. (2019). Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age. AIDS, 33 (11), p. 1797-1799. ISSN 0269-9370.
Titre du document
Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age
Année de publication
2019
Auteurs
Inzaule S. C., Jordan M. R., Cournil Amandine, Vitoria M., Ravasi G., Cham F., Le L. V., Dzangare J., Hamunime N., Mutenda N., Aghokeng Fobang Avelin, Bissek A., Billong S., Kaleebu P., Doherty M., Bertagnolio S.
Source
AIDS, 2019,
33 (11), p. 1797-1799 ISSN 0269-9370
Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safety concerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population.
Plan de classement
Santé : généralités [050]
;
Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
AFRIQUE SUBSAHARIENNE ; AMERIQUE LATINE ; ASIE DU SUD EST
Localisation
Fonds IRD [F B010077424]
Identifiant IRD
fdi:010077424
